- Target disease: Leishmaniasis
- Main partners (since project start): Daiichi Sankyo, Japan
- Project start: 2017
- Funding (since project start): Department for International Development (DFID), UK; Médecins Sans Frontières/Doctors without Borders; Dutch Ministry of Foreign Affairs (DGIS), The Netherlands; Federal Ministry of Education and Research (BMBF through KfW), Germany; Global Health Innovative Technology (GHIT) Fund, Japan; Swiss Agency for Development and Cooperation (SDC), Switzerland.
Current hit-to-lead efforts of the series identified from the Daiichi Sankyo Pharma Space Library focus on Chagas disease, but the project team submits any newly synthesized molecules to a Leishmania cross screen to assess potential.
Last update: August 2018